The NIH's National Center for Advancing Translational Sciences (NCATS) has awarded a total of $12.7 million to 9 academic research groups to repurpose compounds from 5 pharma partners in the center's Discovering New Therapeutic Uses for Existing Molecules program.

According to Christine Colvis, director of the program, the 9 projects were selected from about 160 applicants through an NIH peer review process, and the awards for the first year range from about $500,000 to $3 million (see "NCATS's first repurposing round"). Colvis said that the academic partners would own any new IP generated by the partnership, and the pharmas would have options to license that IP.

Last year, NCATS disclosed details about the first library of therapeutics in the program. Eight pharmas provided the library with a total of 58 compounds that had completed at least Phase I testing but did not reach registration for their original indications.1

Haas, M.J. SciBX 6(25); doi:10.1038/scibx.2013.616 Published online June 27, 2013


1.   Haas, M.J. SciBX 5(26); doi:10.1038/scibx.2012.669

2.   Brunzell, D.H. & McIntosh, J.M. Neuropsychopharmacology 37, 1134-1143 (2012)

3.   Judge, D.P. et al. Am. J. Cardiovasc. Drugs 11, 287-294 (2011)

4.   Vandebrouck, C. et al. J. Cell Biol. 158, 1089-1096 (2002)

5.   Millay, D.P. et al. Proc. Natl. Acad. Sci. USA 106, 19023-19028 (2009)

6.   Watanabe, H. et al. Circ. J. 73, 419-427 (2009)

7.   Horton, J.S. et al. Channels (Austin) 7, 17-22 (2013)


      National Center for Advancing Translational Sciences, Bethesda, Md.

      National Institutes of Health, Bethesda, Md.